Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Kexing Biopharm Co., Ltd. (688136.SS)
Jinan, CN
Kexing Biopharm Co., Ltd. is a global pharmaceutical enterprise primarily involved in the exploration, manufacturing, and commercialization of advanced recombinant protein-based drugs and microbial preparations, serving both the Chinese domestic market and international clientele. The company strategically directs its research and development endeavors towards crucial medical areas, specifically focusing on antiviral therapies, oncology, immunology, hematological conditions, digestive system health, and degenerative diseases. Its extensive product lineup features diverse pharmaceutical solutions. This includes innovative recombinant human proteins such as interferon a1b, erythropoietin, and granulocyte stimulating factor. Additionally, their offerings encompass microbial formulations like Clostridium butyricum combined live bacteria powder, traditional Chinese patent medicines (e.g., Kehuang Capsule), and chemical drugs like Entecavir. Kexing Biopharm also provides cutting-edge biologics, including liraglutide (a human glucagon-like peptide-1), along with other specialized therapeutics such as Albumin-Paclitaxel, Infliximab, Bevacizumab, adalimumab, trastuzumab, neratinib maleate tablets, and lenalidomide capsules. Established in 1989, the company's main operations are situated in Jinan, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.15% | +2.04% | -15.83% | -13.71% | -31.17% | -17.71% | -25.99% | +34.33% | -22.97% | -36.45% | -36.45% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Biotechnology: +1.6%+9.5% ★ Q1'26: -20.7% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+406.3% ★ Q1'26: -169.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+2.6% Q1'26: -1.3% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+11.0% ★ Q1'26: -3.1% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+8.0% ★ Q1'26: -1.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q1'26: -0.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×3.49× Q1'26: -40.66× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
1.26B
est: 1.37B (-8.3%)
|
1.41B
est: 1.47B (-4.2%)
|
1.54B
est: 1.73B (-10.8%)
|
1.63B
1.63B – 1.63B
-5.4% YoY
|
1.88B
1.88B – 1.88B
+15.1% YoY
|
2.08B
2.08B – 2.08B
+10.5% YoY
|
| EBITDA |
-145.88M
est: 48.05M (-403.6%)
|
188.21M
est: 74.45M (+152.8%)
|
255.50M
est: 87.64M (+191.6%)
|
82.89M
82.89M – 82.89M
-5.4% YoY
|
95.37M
95.37M – 95.37M
+15.1% YoY
|
105.36M
105.36M – 105.36M
+10.5% YoY
|
| EBIT |
-218.95M
est: -10.22M (-2,041.4%)
|
102.13M
est: 2.73M (+3,641.8%)
|
169.42M
est: 3.21M (+5,173.3%)
|
3.04M
3.04M – 3.04M
-5.4% YoY
|
3.50M
3.50M – 3.50M
+15.1% YoY
|
3.86M
3.86M – 3.86M
+10.5% YoY
|
| Net Income |
-190.29M
est: -112.15M (-69.7%)
|
31.48M
est: 43.31M (-27.3%)
|
159.44M
est: 108.26M (+47.3%)
|
151.57M
151.57M – 151.57M
+40.0% YoY
|
189.95M
189.95M – 189.95M
+25.3% YoY
|
243.10M
243.10M – 243.10M
+28.0% YoY
|
| SGA |
776.11M
est: 836.74M (-7.2%)
|
682.73M
est: 720.59M (-5.3%)
|
—
est: 848.21M (-100.0%)
|
802.32M
802.32M – 802.32M
-5.4% YoY
|
923.07M
923.07M – 923.07M
+15.1% YoY
|
1.02B
1.02B – 1.02B
+10.5% YoY
|
| EPS |
-0.96
est: -0.57 (-68.4%)
|
0.16
est: 0.22 (-27.3%)
|
0.81
est: 0.55 (+47.3%)
|
0.77
0.77 – 0.77
+40.0% YoY
|
0.97
0.97 – 0.97
+25.3% YoY
|
1.24
1.24 – 1.24
+28.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-24 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Fang Fang Tian | Head of the scientific research management center of the pharmaceutical research institute | — | male |
| Hongjie Ma | Deputy GM & GM of Technology Center | — | female |
| Hui Ming Li | Deputy General Manager of the New Drug Research Center | — | male |
| Ke Shao | Deputy General Manager | — | male |
| Ning Cui | Deputy GM & Director | — | female |
| Shu Ling Wang | Accounting Supervisor | — | — |
| Suofu Qin | Deputy General Manager | — | male |
| Wei Shang | Senior Manager of cell biology - New Drug Research Center | — | female |
| Xiaoqin Wang | Chief Financial Officer, Secretary to the Board & Director | — | female |
| Yanqing Zhao | Chief Executive Officer, GM & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688136.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
